Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karoly Toth

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|May 22, 2024
NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster modelAnn E Tollefson, Anna B Cline-Smith, Jacqueline F Spencer, et al.
Antiviral Research|June 28, 2025
LAVR-289, a broad-spectrum antiviral, protects immunosuppressed Syrian hamsters against lethal adenovirus challengeAnn E Tollefson, Anna Cline-Smith, Vincent Roy, et al.
Journal of Virology|March 3, 2017
Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5Ann E Tollefson, Baoling Ying, Jacqueline F Spencer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 31, 2008
Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster modelMaria A Thomas, Jacqueline F Spencer, Karoly Toth, et al.
Antiviral Research|December 3, 2014
Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this modelAnn E Tollefson, Jacqueline F Spencer, Baoling Ying, et al.
Cancer Research|February 3, 2006
Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectorsMaria A Thomas, Jacqueline F Spencer, Marie C La Regina, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS EnzymeMichael Flanagan, Qi Gan, Saahil Sheth, et al.
RSC Medicinal Chemistry|November 4, 2024
Miniaturized click chemistry and direct screening facilitate the discovery of triazole piperazine SARS-CoV-2 M<sup>pro</sup> inhibitors with improved metabolic stabilityShenghua Gao, Letian Song, Bing Ye, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2006
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinomaMarwan G Fakih, Ashwani Rajput, Gary Y Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2008
Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelKaroly Toth, Jacqueline F Spencer, Debanjan Dhar, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|May 22, 2024
NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster modelAnn E Tollefson, Anna B Cline-Smith, Jacqueline F Spencer, et al.
Antiviral Research|June 28, 2025
LAVR-289, a broad-spectrum antiviral, protects immunosuppressed Syrian hamsters against lethal adenovirus challengeAnn E Tollefson, Anna Cline-Smith, Vincent Roy, et al.
Journal of Virology|March 3, 2017
Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5Ann E Tollefson, Baoling Ying, Jacqueline F Spencer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 31, 2008
Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster modelMaria A Thomas, Jacqueline F Spencer, Karoly Toth, et al.
Antiviral Research|December 3, 2014
Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this modelAnn E Tollefson, Jacqueline F Spencer, Baoling Ying, et al.
Cancer Research|February 3, 2006
Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectorsMaria A Thomas, Jacqueline F Spencer, Marie C La Regina, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS EnzymeMichael Flanagan, Qi Gan, Saahil Sheth, et al.
RSC Medicinal Chemistry|November 4, 2024
Miniaturized click chemistry and direct screening facilitate the discovery of triazole piperazine SARS-CoV-2 M<sup>pro</sup> inhibitors with improved metabolic stabilityShenghua Gao, Letian Song, Bing Ye, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2006
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinomaMarwan G Fakih, Ashwani Rajput, Gary Y Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 21, 2008
Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelKaroly Toth, Jacqueline F Spencer, Debanjan Dhar, et al.
Pageof 7